June 25, 2015 / 12:30 PM / in 2 years

CORRECTED-BUZZ-Aeterna Zentaris Inc: Selects Ergomed to conduct late-stage study

(Corrects company name to “Aeterna” from “Aetena” in headline and text)

** Canadian drug developer’s U.S.-listed shares up 7.4 pct at $0.29 pre-market

** UK-based drug developer Ergomed PLC will manage late-stage confirmatory study of Aeterna’s drug Macrilen, used to evaluate growth hormone deficiency in adults

** Macimorelin, under the trade name Macrilen, has been granted orphan drug designation by the FDA for diagnosis of adult growth hormone deficiency

** Up to Wednesday’s close, Aeterna’s Toronto-listed stock had declined nearly 72 pct over the last 12 months

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below